Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
about
Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.Cilia dysfunction in lung disease.Early pathologic findings of bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a proposal from a caseLate Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.Pediatric lung transplantation: indications and outcomes.A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation.NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT.Clinical significance of nontuberculous mycobacteria from respiratory specimens in stem cell transplantation recipients.Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trial.Successful cord blood transplantation for an HIV-negative patient with refractory plasmablastic lymphoma.Small airways dysfunction in long-term survivors of pediatric stem cell transplantation.Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group.The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
P2860
Q33576014-F50BE9F4-7E6C-421A-90DA-32BDBAB2E46AQ35734837-149E7F83-8D61-4E49-BD45-3781EEA4C299Q36203903-617726A4-1CD2-4B1B-A3AB-AB47408BE822Q36783762-AD9C10C1-839A-4E98-B742-7BE0F29A33DFQ38240864-0493E087-27C4-4F78-A7A6-565D24455762Q39041930-B789B1F1-0F0F-4A04-A46A-380195130F53Q40787485-A2B95F7C-D8B4-48C4-A3AB-402BEE14D6AAQ41456444-4E120F9F-3BD0-43E5-9312-1CB8C1F27265Q41495027-4EB6F393-0DDD-4E58-84AD-48798A101B03Q47134781-B713CBE5-5D97-45E7-A20B-820992E0C7F6Q50213459-FC64F7C0-C98C-4BA4-930A-47608CE96D06Q50456037-BCEB4044-3553-4477-A09E-B0E90F089945Q51153526-710230E0-5631-4BD8-BF25-C0C476BA73F1Q52934357-0349C137-A4E6-4D08-801A-3E0A9FD46B98
P2860
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
@en
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
@nl
type
label
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
@en
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
@nl
prefLabel
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
@en
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.
@nl
P2093
P2860
P356
P1476
Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options
@en
P2093
C J Heilmann
F Buchvald
H H Uhlving
P2860
P2888
P304
P356
10.1038/BMT.2011.161
P407
P577
2011-08-29T00:00:00Z